. 2017 Sep 14;14(5):5743–5752. doi: 10.3892/ol.2017.6933

Table IV.

Association between uridine diphosphate glucuronosyltransferase 1A*28 and irinotecan ADR.

	After the first cycle						During the entire course of chemotherapy

	Grade 3–4, n			Grade 1–4, n			Grade 3–4, n			Grade 1–4, n

Adverse event	TA₆/TA₆	TA₆/TA₇	P-value	TA₆/TA₆	TA₆/TA₇	P-value	TA₆/TA₆	TA₆/TA₇	P-value	TA₆/TA₆	TA₆/TA₇	P-value
Total	86	19		56	12		86	19		56	12
Hematological
Neutropenia	9	6	0.028^a	31	7	0.948	18	7	0.157	50	10	0.917
Leukopenia	4	6	0.002^a	33	8	0.763	8	7	0.006^a	50	11	0.896
Hemoglobin reduction	4	0	1.000	27	6	0.998	6	0	0.590	40	8	0.663
Non-hematological
Diarrhea	16	2	0.517	43	8	0.553	17	3	1.000	47	9	1.000
Cholinergic syndrome				13	3	1.000				14	4	0.738
Total ADR	23	7	0.378	65	14	1.000	34	8	0.896	74	16	0.703

P<0.05. Pearson's χ² and Fisher's exact tests comparing neutropenia, leukopenia, hemoglobin reduction, diarrhea, cholinergic syndrome and total ADR between patients with and without TA₆/TA₇. ADR, adverse drug reaction.